The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years-Reference-Cited by-同舟云学术

The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years

Published:2022-04-12 Issue:6 Volume:36 Page:1646-1653
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Bazarbachi Ali^ORCID,Boumendil Ariane,Finel Hervé,Khvedelidze Irma,Romejko-Jarosinska Joanna,Tanase Alina,Akhtar Saad,Ben Othman Tarek,Ma’koseh Mohammad,Afanasyev Boris,Cheikh Jean^ORCID,Briones Javier,Gülbas Zafer,Hamladji Rose-Marie,Elverdi Tugrul,Blaise Didier^ORCID,Martínez Carmen,Alma Eleonora,Halaburda Kazimierz,Sousa Aida Botelho,Glass Bertram,Robinson Steven,Montoto Silvia^ORCID,Sureda Anna

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-022-01563-8.pdf

Reference37 articles.

1. Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: importance of disease status at transplant. J Clin Oncol. 1993;11:704–11.

2. Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case- control study. Societe Francaise de Greffe de Moelle. J Clin Oncol. 1999;17:222–9.

3. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–4.

4. Holmberg L, Maloney DG. The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma. J Natl Compr Canc Netw. 2011;9:1060–71.

5. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood. 2005;106:1473–8.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-09-06

2. Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report;Frontiers in Immunology;2024-03-06

3. Classical Hodgkin’s Lymphoma;The EBMT Handbook;2024

4. Trends in Outcome of Hematopoietic Stem Cell Transplantation: 5000 Transplantations and 30 Years of Single-Center Experience;Cancers;2023-09-28

5. Higher efficacy of Etoposide + Cytarabine Plus Pegfilgrastim in poorly mobilizing Multiple Myeloma and lymphoma Patients;Cytotherapy;2023-08